EasyM: Blood-based MRD for MM

Rapid Novor EasyM is a non-invasive, blood-based MRD test for MM, tracking unique M-protein peptides via mass spectrometry for precise monitoring.

[EasyM: Blood-based MRD for MM @easym_test]

Heading into #ASCO25 we're happy to share our latest paper with the #myeloma community. Dr. Slade has been instrumental to helping EasyM develop its state-of-the art non-invasive #mmMRD assay and we look forward to the next !

EasyM is a CLIA certified LDT and not FDA approved

[EasyM: Blood-based MRD for MM @easym_test]

🍁 What a fantastic weekend of learning, collaboration, and connection at the @MyelomaCanada Scientific Roundtable!

The EasyM team was grateful to be part of this important event, where we had the opportunity to present and highlight EasyM, our blood-based MRD test for multiple myeloma (MM), which is clinically available in both the United States and Canada.

A huge thank you to everyone who took the time to connect, engage with us, and share their insights. We are so grateful for opportunities like this that bring the myeloma community together to exchange knowledge, advance science, and continue pushing innovation forward - all with one shared goal: improving outcomes for patients.

💡 Questions about accessing EasyM? Contact us at [email protected]!

@HiraSMian #MM #MRD #MinimalResidualDisease #MMSM #CancerResearch #PatientCare

[EasyM: Blood-based MRD for MM @easym_test]

📢 Exciting News - Abstracts for #ASH2026 are posted!!!

We are proud to be presenting our research this year investigating our mass spectrometry (MS) based assay for the quantification of soluble B-cell maturation antigen (sBCMA) in multiple myeloma (MM) serum samples.

💡 The study found that our MS-based assay had good correlation to sBCMA ELISA in MM patients, demonstrating the potential to monitor disease burden in MM patients, regardless of their M-protein type.

In addition, we collaborated on a study with Washington University School of Medicine in St. Louis, to describe post-chimeric antigen receptor (CAR) T cell M-protein kinetics, using clonotypic mass spectrometry (CT-MS).

💡  Findings demonstrate that CT-MS is highly sensitive for relapse, with detectable and increasing M-protein in 100% of relapse samples. Achieving undetectable CT-MS was highly dependent on M-protein half-life.

Read the full abstracts here:

4067: Mass Spectrometry Assay to Quantify B-Cell Maturation Antigen in Serum of Patients with Multiple Myeloma: https://t.co/zuok9rRida

4071: M-Protein Kinetics via Clonotypic Mass Spectrometry Following BCMA-Directed CAR T Cell Therapy: https://t.co/0Kpb6dbijn

#MultipleMyeloma #MM #MRD #MinimalResidualDisease #MMSM #CART #BCMA #MassSpec

[EasyM: Blood-based MRD for MM @easym_test]

The EasyM Team is Attending the @MyelomaCanada 2026 Scientific Roundtable! ✈️💼

We look forward to engaging in valuable discussions, sharing ideas, and connecting with myeloma experts, scientists, industry partners, and patients! Above all, we are incredibly excited to continue driving meaningful progress in Multiple Myeloma research to improve patient outcomes.

If you are attending, let's connect! We would love to discuss how we can collaborate, share insights, and continue driving meaningful progress in Multiple Myeloma.

📅 When: November 6 - 7, 2026
📍 Where: Montreal, Quebec
👇 Attending? Drop a comment below, or send us a DM to set up a meet-up! See you in Montreal! 🤝

#EasyM #MultipleMyeloma #MM #MRD #MinimalResidualDisease #MMSM

[EasyM: Blood-based MRD for MM @easym_test]

The EasyM team was thrilled to attend the Canadian Myeloma Research Group (CMRG) conference in Toronto this past weekend! It was a fantastic opportunity to connect and dive into exciting new developments in multiple myeloma.

A monumental highlight of the weekend was the special announcement of a $6 million donation to the London Health Sciences Foundation. This targeted funding will develop a national translational CMRG Biobank infrastructure centered at London Health Sciences Centre (LHSC), standardizing sample acquisition and fostering a network for collaboration across Canada!

The presentations showcased remarkable scientific progress and highlighted critical next steps for the community:

Clinical Access & Innovation: Deep discussions on the Canadian landscape for relapsed/refractory myeloma, spotlighting the urgent need for routine access to novel immunotherapies, including CAR T-cell therapies and bispecific antibodies like talquetamab.

Translational Research: Exploring the future of disease tracking through functional imaging and advanced blood-based mass spectrometry.

Global Collaboration: Inspiring clinical trial data and collaborative frameworks shared by international partners, including the UK Myeloma Research Alliance and the Greek and Balkan Myeloma Study Groups.

Patient-Centricity: Emphasizing the integration of patient and carer voices into clinical trial design to ensure primary endpoints truly reflect what matters most to those undergoing treatment.

Thank you to the organizers and esteemed panelists for making this such an impactful and collaborative experience. We look forward to seeing how these incredible developments continue to drive healthcare science and patient access forward!

@ResearchMyeloma @LHSCCanada

#CMRG #MyelomaResearch #ClinicalTrials #MultipleMyeloma #MM #MMSM #MRD

[EasyM: Blood-based MRD for MM @easym_test]

New research for blood-based monitoring in multiple myeloma🩸

EasyM uses clonotypic mass spectrometry to track patient-specific myeloma proteins through a simple blood test, offering a less invasive approach to monitoring disease over time.

Clinically available in 🇨🇦 Canada and 🇺🇸 the United States.

🎥 Watch the video to learn more about the latest research: https://t.co/HQdty5RwUF

#MultipleMyeloma #MRD #PRD #mmsm #IMS2026 @HealthTree @MyelomaTeacher

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

Blood-Based MRD Testing Correlates With Bone Marrow Testing in Multiple #Myeloma -#EasyM | #IMS2026 #mmsm
https://t.co/fa9YRTfYtG

[EasyM: Blood-based MRD for MM @easym_test]

💡 New research presented at #IMS2026

How can we make multiple myeloma monitoring less invasive while gaining valuable insights into disease status over time?

Our latest research, “Prospective Study of Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EasyM) in Patients with Newly Diagnosed Multiple Myeloma,” explores the potential of EasyM as a blood-based approach to monitoring PRD.

Key highlights from this ongoing prospective study:
• Patient-specific clonotypic peptides were successfully identified in all 70 eligible patients.
• Early results showed concordance between EasyM-based PRD assessments and bone marrow minimal residual disease (MRD) measured by next-generation flow (NGF).
• Findings suggest that EasyM may offer a less invasive approach to longitudinal disease monitoring, complementing conventional bone marrow MRD assessments.

While further follow-up is needed to validate these preliminary findings, the study highlights the potential of clonotypic mass spectrometry to support a more accessible, patient-specific approach to multiple myeloma monitoring.

📄 Read the abstract: https://t.co/wcOKMxOUiq

#MultipleMyeloma #MM #MMSM #MRD #PRD #MassSpectrometry #MinimalResidualDisease

[EasyM: Blood-based MRD for MM @easym_test]

It was a pleasure to attend the @MyelomaCanada MRD Harmonization Workshop and connect with experts working to advance MRD testing in multiple myeloma for Canadians.

It was also a great opportunity to share that EasyM is available across Canada and to introduce more of the community to our blood-based solution.

Thank you to Myeloma Canada and everyone involved for the insightful discussions and collaboration. We’re proud to be part of this important conversation!

#MyelomaCanada #MultipleMyeloma #MRD #MM #MMSM

[EasyM: Blood-based MRD for MM @easym_test]

A big thank you to the Hematology team at Grand River Hospital for welcoming us for a Lunch & Learn!

We enjoyed connecting with your team, sharing insights, and discussing the evolving field of blood-based MRD testing. 🩸

It was a pleasure to introduce EasyM and share more about our blood-based MRD technology for multiple myeloma and the exciting advances in this space.

💭 Interested in learning more about EasyM? Send us a DM - we’d love to connect and arrange a Lunch & Learn with your team!

#MM #MRD #MMSM #MultipleMyeloma

[EasyM: Blood-based MRD for MM @easym_test]

What an incredible #IMS2026 ⭐️

An amazing meeting filled with groundbreaking data, excellent presentations and posters, and so many inspiring connections across the myeloma community.

One theme that stood out was the rapidly evolving role of blood-based techniques for sensitive, longitudinal disease tracking.🩸

The new IMS/IMWG consensus definition of cure, incorporating sustained MRD negativity over 5 years off treatment, further highlights how central sensitive MRD assessment is becoming in the future of myeloma care.

Thank you to everyone who we connected with it was such a pleasure 🤝

#MM #MMSM #MultipleMyeloma #MRD

[EasyM: Blood-based MRD for MM @easym_test]

✈️ The EasyM Team is wheels up!

We’re heading to #IMS2026 meeting and are excited to share our latest work with the myeloma community.

📌 Poster # PA-373

“Prospective Study of Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EasyM) in Patients with Newly Diagnosed Multiple Myeloma”

Looking forward to sharing our findings, connecting with colleagues, and exchanging ideas on the future of multiple myeloma research.

Visit our booth or DM us to set up a time to chat - see you in Glasgow! 🤝

#MM #MRD #MMSM #MultipleMyeloma

[EasyM: Blood-based MRD for MM @easym_test]

🩸💪 ONE WEEK TO DOUBLE YOUR IMPACT!

On September 25 at 2 PM ET, every donation to the EasyM team will be matched by us, meaning your support can go twice as far.

👉 Support the EasyM team: https://t.co/BmyMKvgbWQ

Every donation supports Myeloma Canada | Myélome Canada and helps bring us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.
One week. Double the impact. Together, let’s make a difference. ❤️

#MyelomaMarch #MultipleMyeloma #MM #MRD #MyelomaCanada #MyelomaResearch #PatientAdvocacy

[EasyM: Blood-based MRD for MM @easym_test]

The EasyM team is excited to be attending the International Myeloma Society (IMS) 2026 Annual Meeting in Glasgow next week! 🎉

We’re looking forward to connecting, learning the latest advances in myeloma research, and having great conversations with the community.

Will you be at IMS 2026? DM us to set up a time to meet, we’d be happy to chat! 🤝

See you in Glasgow!

#IMS2026 #MultipleMyeloma #MyelomaResearch #MM #MMSM #MRD

[Hira Mian @HiraSMian]

We are almost there! Help us get to our goal https://t.co/Es8Pyj32k1 @McMasterOnc @McMasteResearch @HamiltonMyeloma @HamHealthSci @MyelomaCanada

[EasyM: Blood-based MRD for MM @easym_test]

🩸💪 We’re 50% of the way to our goal!

DOUBLE YOUR IMPACT 🙌

At 2 PM ET on September 25 all donations will be matched by us!

👉 Support the EasyM team: https://t.co/3EDuawpnHX

Every donation supports @MyelomaCanada and brings us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.

Together, let's make a difference ❤️

#MyelomaMarch #MultipleMyeloma #MM #MRD #MyelomaCanada #MyelomaResearch #PatientAdvocacy #EasyM #RapidNovor

[EasyM: Blood-based MRD for MM @easym_test]

Early treatment failure after CAR-T: can we identify patients at risk?

A new study of patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) found that:

• Prior BCMA-directed therapy, extramedullary disease, and CAR-HEMATOTOX ≥2 were independent predictors of early progression or death.
• MRD positivity at 3 months was associated with a significantly higher risk of early treatment failure.
• Less than complete response on FDG PET/CT at 3 months was also strongly associated with early treatment failure.

These findings highlight the potential value of early and sensitive disease monitoring after CAR-T, particularly for identifying patients who may need closer follow-up or new therapeutic strategies.

📄 Read the study: https://t.co/gZYN3BKAvE

#MultipleMyeloma #CART #CiltaCel #MRD #MassSpectrometry #MyelomaResearch #PrecisionMedicine #EasyM #MMSM

[EasyM: Blood-based MRD for MM @easym_test]

🩸 September is Blood Cancer Awareness Month 🩸

Did you know Multiple Myeloma is the 2nd most common blood cancer in the world?

This month and always, we pledge to:

- Stand with patients and families
- Raise awareness of Multiple Myeloma
- Drive research forward

Every share, every conversation, and every act of support brings us one step closer to a future with better options for all.

#BloodCancerAwareness #MultipleMyeloma #KnowMyleoma #MM #MMSM

[EasyM: Blood-based MRD for MM @easym_test]

Step Up for Canadians Living with Multiple Myeloma 🩸💪

On September 27, the EasyM team will join the Kitchener-Waterloo Multiple Myeloma March in support of @MyelomaCanada

Your donation helps:
- Advance research toward better treatments and outcomes
- Strengthen patient advocacy and access to new therapies

Double your impact ‼️

Donate by September 25 and your contribution could go twice as far.
At 2 PM ET on September 25, 2026, we will match the total amount raised by our team at that time, effectively doubling every donation made.

Every donation brings us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.

Support our team and help us reach our goal:
https://t.co/ayC447P3iD

Together, every step makes a difference.

#MyelomaMarch #MultipleMyeloma #MM #MRD #MyelomaCanada #MyelomaResearch #PatientAdvocacy #EasyM #RapidNovor

[EasyM: Blood-based MRD for MM @easym_test]

📈 Sustained MRD negativity matters in newly diagnosed multiple myeloma.

In a cohort of 335 patients, sustained MRD-negative status was associated with significantly better PFS, while even one MRD-positive result predicted worse outcomes.

The study suggests that durable MRD negativity may outweigh the impact of high-risk cytogenetics and highlights the clinical value of serial MRD monitoring.

Read the abstract here: https://t.co/Xyk4GxQMhV

#MultipleMyeloma #MMSM #MRD #Hematology #Oncology #ASCO